未找到相关数据
Updated results of a phase 1b/2 study of surufatinib plus camrelizumab, nab-paclitaxel and S-1 (NASCA) as first-line therapy for metastatic pancreatic adenocarcinoma (mPDAC).
被引：2
作者：
Jia, Ru
Si, Hai-Yan
Wang, Zhi-Kuan
Deng, Guo-Chao
Zhang, Nan
Liu, Fang-Fang
Shi, Yue
Zhang, Yao-Yue
Jia, Yu-Shan
Wang, Yanrong
Fan, Meng-Jiao
Miao, Meng-Meng
Zhang, Bei
Tong, Shuang
Dai, Guang-Hai
机构：
[1] Peoples Liberat Army Gen Hosp, Med Ctr 5, Sr Dept Oncol, Beijing, Peoples R China
[2] HUTCHMED Ltd, Shanghai, Peoples R China
[3] 3D Med, Med Affairs, Shanghai, Peoples R China
关键词：
283-2494;
283-237-2581-242;
3282-3301-4686-3729-3519-4685-2424;
261-492-199-2823-5450;
261-492-2769;
613-135-244-3829;
3282-3301-4686-3729-3519-4685-2805;
6;
4;
3;
2;
4062;
219;
2950;
3618;
38092-23304;
38092-20111;
38092-27449;
38092-20125;
38092-20072;
38092-20047;
1;
D O I：
10.1200/JCO.2024.42.3_suppl.671
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：671 / 671
页数：1
相关论文